hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06331598, orgStudyIdInfo id: ML43332, secondaryIdInfos id: 2022-003708-33, type: EUDRACT_NUMBER, briefTitle: A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H), acronym: IMperator, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-30, primaryCompletionDateStruct date: 2028-10-20, completionDateStruct date: 2029-09-20, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Hoffmann-La Roche, class: INDUSTRY, descriptionModule briefSummary: This study is being conducted to evaluate efficacy parameters (disease free survival \[DFS\] and overall survival \[OS\]) of atezolizumab and atezolizumab in combination with tiragolumab in TMB-H or MSI-H as adjuvant treatment after standard radical intended treatment in participants with intermediate-high risk of recurrence., conditionsModule conditions: Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Atezolizumab, interventions name: Tiragolumab, outcomesModule primaryOutcomes measure: Disease Free Survival (DFS) Rate at 24 Months, secondaryOutcomes measure: DFS Rate at 36, 48 and 60 Months, secondaryOutcomes measure: OS (Overall Survival), secondaryOutcomes measure: Percentage of Participants With Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital Universitari Vall dHebron; Oncology, status: RECRUITING, city: Barcelona, zip: 08035, country: Spain, geoPoint lat: 41.38879, lon: 2.15899, locations facility: Hospital Universitario Virgen; Servicio de Oncologia, status: RECRUITING, city: Sevilla, zip: 41013, country: Spain, geoPoint lat: 37.38283, lon: -5.97317, hasResults: False
protocolSection identificationModule nctId: NCT06331585, orgStudyIdInfo id: KY-2024004, briefTitle: Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy, statusModule overallStatus: WITHDRAWN, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2025-03-18, completionDateStruct date: 2026-03-18, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Hetian District People's Hospital, class: OTHER, descriptionModule briefSummary: The purpose of this phase Ⅱ trial was to investigate the effect of low-dose radiotherapy (LDRT) on the tumor immune microenvironment (TME) in oligometastasis, oligoprogression, and oligopersistence of non-small cell lung cancer (NSCLC) after immunotherapy. At least 20 participants will be enrolled in this study. All will take part at Hetian District People's Hospital., conditionsModule conditions: Low-dose Radiotherapy, conditions: Tumor Microenvironment, conditions: Non-Small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 0, type: ACTUAL, armsInterventionsModule interventions name: low dose radiotherapy, outcomesModule primaryOutcomes measure: Analysis of the tumor immune microenvironment, secondaryOutcomes measure: Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measurement of Safety and Tolerability of Low Dose Radiotherapy, secondaryOutcomes measure: Progression Free Survival (PFS), secondaryOutcomes measure: Overall Survival (OS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hetian District People's Hospital, city: Hetian, state: Xinjiang Uygur Autonomous Region, zip: 848000, country: China, hasResults: False
protocolSection identificationModule nctId: NCT06331572, orgStudyIdInfo id: 1stChongqingMU-TRD, briefTitle: Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-08-01, primaryCompletionDateStruct date: 2021-10-25, completionDateStruct date: 2023-12-20, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: First Affiliated Hospital of Chongqing Medical University, class: OTHER, descriptionModule briefSummary: This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD., conditionsModule conditions: Psychiatric Disorder, conditions: Major Depressive Disorder, conditions: Metabolic Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 162, type: ACTUAL, armsInterventionsModule interventions name: 17-HAMD, outcomesModule primaryOutcomes measure: 17 items Hamilton Depression Scale, secondaryOutcomes measure: Hamilton Anxiety Scale, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Chongqing Medical University, city: Chongqing, state: Province, zip: 400000, country: China, geoPoint lat: 29.56278, lon: 106.55278, hasResults: False
protocolSection identificationModule nctId: NCT06331559, orgStudyIdInfo id: SIM0501-101, briefTitle: Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-19, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Jiangsu Simcere Pharmaceutical Co., Ltd., class: INDUSTRY, collaborators name: Shanghai Xianxiang Medical Technology Co., Ltd., descriptionModule briefSummary: This is an open-label, multicenter Phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0501 in participants with advanced solid tumors. The trial consists two parts, Part 1 for SIM0501 monotherapy and Part 2 for SIM0501 in combination with olaparib. In both parts, SIM0501 with/without olaparib will be administered until disease progression or the investigator determines that continuation of the study drug would not benefit, or there is intolerable toxicity, or the participant or legal representative voluntarily requests withdrawal, or the trial is terminated., conditionsModule conditions: Advanced Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 176, type: ESTIMATED, armsInterventionsModule interventions name: SIM0501 Tablets, interventions name: SIM0501 Tablets, interventions name: SIM0501 in combination with olaparib, interventions name: SIM0501 in combination with olaparib, outcomesModule primaryOutcomes measure: Dose-limiting toxicity (DLT), primaryOutcomes measure: Adverse events will be evaluated according to the CTCAE v5.0, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shandong Cancer Hospital, status: RECRUITING, city: Jinan, state: Shandong, zip: 250117, country: China, contacts name: Jinming Yu, role: CONTACT, phone: 0531-67626971, email: sdyujinming@126.com, geoPoint lat: 36.66833, lon: 116.99722, hasResults: False
protocolSection identificationModule nctId: NCT06331546, orgStudyIdInfo id: IRB300004693, secondaryIdInfos id: R01DK137784, type: NIH, link: https://reporter.nih.gov/quickSearch/R01DK137784, briefTitle: Gut Oxalate Absorption in Calcium Oxalate Stone Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2030-12-31, completionDateStruct date: 2031-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University of Alabama at Birmingham, class: OTHER, collaborators name: University of Texas Southwestern Medical Center, collaborators name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), descriptionModule briefSummary: The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased absorption of dietary oxalate, which would lead to increased urinary excretion of oxalate.The study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones.Participants will* ingest fixed diets containing low and moderately high amounts of oxalate for 5 days at a time* ingest a soluble form of oxalate and sugar preparations to test gut permeability* collect urine, blood, stool and breath sample during the fixed diets and the soluble oxalate test, conditionsModule conditions: Kidney Stone, conditions: Kidney Calculi, conditions: Urolithiasis, conditions: Urolithiasis, Calcium Oxalate, conditions: Nephrolithiasis, conditions: Nephrolithiasis, Calcium Oxalate, conditions: Oxalate Urolithiasis, conditions: Oxaluria, conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Low-oxalate diet, interventions name: High-oxalate diet, interventions name: soluble oxalate gut absorption test, outcomesModule primaryOutcomes measure: Net Gastrointestinal absorption of food-bound oxalate, secondaryOutcomes measure: Absorption of soluble 13C2-oxalate, secondaryOutcomes measure: Estimated endogenous oxalate synthesis (oxalate mg/day), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Alabama at Birmingham, status: RECRUITING, city: Birmingham, state: Alabama, zip: 35294, country: United States, contacts name: Sonia Fargue, PhD, role: CONTACT, phone: 205-975-6932, email: kidneystone@uabmc.edu, contacts name: Research Coordinator, role: CONTACT, phone: 205-9345712, email: kidneystone@uabmc.edu, contacts name: Sonia Fargue, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.52066, lon: -86.80249, locations facility: UTSW, status: ACTIVE_NOT_RECRUITING, city: Dallas, state: Texas, zip: 75390, country: United States, geoPoint lat: 32.78306, lon: -96.80667, hasResults: False
protocolSection identificationModule nctId: NCT06331533, orgStudyIdInfo id: IstanbulTRH1, briefTitle: Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-11-01, primaryCompletionDateStruct date: 2023-05-01, completionDateStruct date: 2023-06-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Istanbul Training and Research Hospital, class: OTHER_GOV, descriptionModule briefSummary: Investigation of the effectiveness of intradermal botulinum toxin A treatment in the treatment of erythematotelangiectatic rosacea (ETR) using clinical, biophysical, dermatoscopic and videocapillaroscopy., conditionsModule conditions: Erythematotelangiectatic Rosacea, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: Randomized, split face, efficacy study, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Botulinum toxin will be injected into one randomly selected half of the face, and placebo will be injected into the other half of the face. The patient will not know which half of the face was treated. An independent, blinded dermatologist will evaluate the results of the treatment., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Botulinum toxin A, interventions name: Placebo, outcomesModule primaryOutcomes measure: Assessment of erythema with Clinician's Erythema Assessment scale, primaryOutcomes measure: Evaluation of erythema using mexameter, primaryOutcomes measure: Evaluation of erythema by dermatoscopy, secondaryOutcomes measure: Evaluation of the change in vascular structure using videocapillaroscopy, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Istanbul Training and Research Hospital, city: Istanbul, zip: 34098, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06331520, orgStudyIdInfo id: Desineo, briefTitle: NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2026-05-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: The objective of this Prospective, randomized, non inferiority phase III trial is to confirm the efficacy and saftey of dexamethasone-sparing combined with netupitant/palonostron and olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy., conditionsModule conditions: Chemotherapy-induced Nausea and Vomiting, conditions: Highly Emetogenic Chemotherapy, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 627, type: ESTIMATED, armsInterventionsModule interventions name: Netupitant / Palonosetron Oral Capsule [Akynzeo], interventions name: Olanzapine, interventions name: Dexamethasone Oral, outcomesModule primaryOutcomes measure: Percentage of patients with complete response (CR), secondaryOutcomes measure: Percentage of Patients With CR (acute and delayed), secondaryOutcomes measure: Percentage of patients with overall complete protection(OCP), secondaryOutcomes measure: Percentage of patients with overall total control (OTC), secondaryOutcomes measure: incidence of adverse events, secondaryOutcomes measure: quality of life questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06331507, orgStudyIdInfo id: HUM00176904, briefTitle: Refinement and Assessment of New MRI Technologies for Cardiovascular Exams Using the Phillips CMR Patch, statusModule overallStatus: TERMINATED, startDateStruct date: 2021-09-02, primaryCompletionDateStruct date: 2023-06-29, completionDateStruct date: 2023-06-29, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: University of Michigan, class: OTHER, collaborators name: Philips Health Care, descriptionModule briefSummary: This study is being done to improve image quality and provide the collaborator with feedback on wide band imaging in patients with cardiac implantable electronic devices (CIED)., conditionsModule conditions: Cardiomyopathies, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 292, type: ACTUAL, armsInterventionsModule interventions name: CMR patch, outcomesModule primaryOutcomes measure: Scan speed:, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Michigan Medicine - University of Michigan, city: Ann Arbor, state: Michigan, zip: 48109, country: United States, geoPoint lat: 42.27756, lon: -83.74088, hasResults: False
protocolSection identificationModule nctId: NCT06331481, orgStudyIdInfo id: 0005-22-HYMC, briefTitle: The Effect of Over Weight on Oocytes Quality in IVF Patients, acronym: IVF, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-02-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Hillel Yaffe Medical Center, class: OTHER_GOV, descriptionModule briefSummary: Obesity is an increasing worldwide problem and a risk factor for many diseases. The effect of obesity on female fertility has been extensively tested. Obese women have increased time to pregnancy and remain subfertile even in the absence of ovulatory dysfunction. They present with higher incidence of infertility compared to normal weight women.This study is prospective observational cohort study performed between February 2022 until June 2022 in a single university-affiliated hospital., conditionsModule conditions: IVF, conditions: Overweight, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ACTUAL, armsInterventionsModule interventions name: Fullicular fluid for cytology and biocemical analysis, outcomesModule primaryOutcomes measure: Impact of obesity on oocyte's mtDNA expression in Cumulus Cells, primaryOutcomes measure: Impact of obesity on oocyte quality through levels of protein BMP-15, primaryOutcomes measure: Impact of obesity on oocyte quality through levels of protein HSPG2, secondaryOutcomes measure: Impact of obesity on fertilization and pregnancy rates through analysis of mtDNA expression, secondaryOutcomes measure: Impact of obesity on fertilization and pregnancy rates through levels of protein BMP-15, secondaryOutcomes measure: Impact of obesity on fertilization and pregnancy rates through levels of protein HSPG2, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Hillel Yaffe Medical Center - IVF Unit, city: Hadera, zip: 38100, country: Israel, geoPoint lat: 32.44192, lon: 34.9039, hasResults: False
protocolSection identificationModule nctId: NCT06331455, orgStudyIdInfo id: 23-5501, briefTitle: Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection, acronym: SUPER, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Marc de Perrot, class: OTHER, collaborators name: Ozmosis Research Inc., descriptionModule briefSummary: The SUPER trial is a prospective Phase II trial. It is designed for patients with stage 2 or 3 non-small cell lung cancer (NSCLC) prior to surgery.Patients who are enrolled in this trial will receive combination of Non-ablative oligofractionated radiation (NORT) and two cycles of Durvalumab, an immunotherapy drug before their surgery., conditionsModule conditions: Lung Cancer Patients, conditions: Non-small Cell Lung Cancer (NSCLC), designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This is a multi-centre, phase 2 trial in patients with T2b-3N0-1M0 NSCLC evaluating the biologic efficacy of NORT-Durvalumab administered prior to surgery., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Durvalumab, interventions name: Non-ablative oligofractionated radiation (NORT), outcomesModule primaryOutcomes measure: To Measure CD8 TILs density & Major Pathological Response (MPR), secondaryOutcomes measure: To explore the efficacy and safety of NORT-durvalumab, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06331442, orgStudyIdInfo id: 006503905, briefTitle: The Effect of Photodynamic Therapy on Plaque in Orthodontic Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2024-11, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: University of Zagreb, class: OTHER, descriptionModule briefSummary: This randomized controlled trial will be conducted on 40 orthodontic patients at the Department of Orthodontics, University Hospital Centre Zagreb, Croatia. Respondents will be randomly allocated into 4 groups (n=10). The first group will receive photodynamic therapy, the second tricalcium phosphate varnish with 5% NaF (sodium fluoride), the third 1% chlorhexidine varnish, while the fourth group will be the negative control. Before and after the mentioned interventions, the participants will have the amount of plaque measured using the plaque index and the bacteriological composition of the plaque assessed using the mass spectrometry and PCR. The gingival condition will be assessed using the gingival index. Also, the occurrence of white spot lesions will be evaluated on intraoral photographs., conditionsModule conditions: Plaque, Dental, conditions: Dental Plaque Induced Gingivitis, conditions: White Spot Lesion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Photodynamic therapy, interventions name: Tricalcium phosphate (TCP) varnish with 5% NaF, interventions name: Chlorhexidine varnish, outcomesModule primaryOutcomes measure: Assessment of dental plaque accumulation using plaque index, primaryOutcomes measure: Assessment of the bacteriological composition of supragingival plaque using mass spectrometry, secondaryOutcomes measure: Assessment of the bacteriological composition of subgingival plaque using polymerase chain reaction, secondaryOutcomes measure: Assessment of gingival condition using gingival index, secondaryOutcomes measure: Diagnosis of white spot lesions on intraoral photographs, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False